UK Vaccines Market Size, Share, Competitive Landscape and Trend Analysis Report, by Technology Type, by Indication, by End User : Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics

The UK vaccines market growth is driven by increased government investments in vaccination programs, rise in awareness regarding preventive healthcare, and need to combat emerging infectious diseases. In addition, public awareness and increased emphasis on immunization programs are further driving the growth during the UK vaccines market forecast period. Moreover, rise in threat of new infectious diseases, such as future influenza strains, increases the need for vaccines and has prompted pharmaceutical companies to invest in research and development. However, there are also significant restraining factors that may slow down the UK vaccines market growth. High costs associated with vaccine research, development, and distribution pose a challenge, particularly for newer vaccine types that require advanced technology.

On the other hand, increase in emphasis on public health, government support for vaccine research, and rise of novel mRNA technologies provides UK vaccines market opportunity. There is rise in focus on improving adult immunization rates, expanding the national vaccination program, and investing in manufacturing capabilities. Emerging opportunities include developing vaccines for neglected diseases and capitalizing on partnerships between biotech companies and universities. Strong public trust in vaccines and evolving technology platforms also support the market's expansion, positioning the UK as a hub for vaccine innovation and production in the coming years.

Market Segmentation

The UK vaccines market share is segmented on the basis of technology type, indication, and end user. On the basis of technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. On the basis of indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP) , polio, hepatitis, and other indications. On the basis of end user, the market segmented into pediatric, adults, and travelers.

Industry Trends 

• During the 2023-2024 influenza season, the UK experienced a singular peak in influenza activity around the end of January 2024, contrasting with the previous season's dual peaks, one in autumn and another in mid-winter. The data reflects that the average number of confirmed cases during this latest season (256 cases) was significantly lower than the previous season's peak (593 cases) , but higher than the pre-pandemic average (166 cases) . This trend fosters market growth by necessitating continuous updates to vaccine formulations and outreach strategies. 
• From September 2023, the Gov. UK has implemented significant changes to its Human Papillomavirus (HPV) vaccination program, primarily moving from a two-dose to a one-dose schedule for certain groups. This decision is based on recommendations from the Joint Committee on Vaccination and Immunisation (JCVI) , which found that a single dose provides comparable protection against HPV infection as the previous two-dose regimen. 
• For instance, according to the Gov.UK, the coverage for the prenatal pertussis vaccine among pregnant women was reported at 59.3% for the last quarter of 2023, which reflects a slight decrease from the previous year. This vaccine is crucial for protecting newborns from pertussis until they can receive their first dose at eight weeks. 

Competitive Landscape 

The key players operating in the UK vaccines industry include Pfizer, Valneva SE, Viatris Inc., AstraZeneca, Emergex Vaccines, GSK plc., Sanofi, Bavarian Nordic A/S, Prokarium, and Merck & Co., Inc. These players have adopted various developmental strategies to stay competitive in the market. For instance, in July 2024, Valneva SE?a specialty vaccine company announced that the European Commission (EC) granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.

Key Benefits for Stakeholders

• Enable informed decision-making process and offer market analysis based on current market situation and estimated future UK vaccines market trends.
• Analyze the key strategies adopted by major market players in UK vaccines market.
• Assess and rank the top factors that are expected to affect the growth of UK vaccines market share.
• Top Player positioning provides a clear understanding of the present position of market players.
• Detailed UK vaccines market analysis of segmentation assists to determine the prevailing market opportunities.
• Identify key investment pockets for various offerings in the market.